Sanofi forking out $3.7 billion to buy California biopharma company

17 August 2020

Confirming rumors that started in July, French pharma major Sanofi (Euronext: SAN) said today that it will acquire Principia Biopharma (Nasdaq: PRNB), a late-stage, California-based biopharmaceutical company focused on developing treatments for immune-mediated diseases.

Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of around $3.68 billion (on a fully diluted basis). This is a 10% premium to Principia’s closing price of $90.74 on Friday, and the news sent the stock up 11.3% to $101.00 pre-market this morning. The Sanofi and Principia boards of directors unanimously approved the transaction.

In 2017, Sanofi formed a collaboration with Principia under which Principia granted Sanofi an exclusive, worldwide license to develop and commercialize BTK inhibitor ‘168 in multiple sclerosis and other central nervous system diseases. Sanofi already has two blockbuster MS drugs of its own, in the form of Aubagio (teriflunomide) and Lemtrada (alemtuzumab).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK